Liberty Broadband Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Liberty Broadband Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.58M | Feb 8, 2019 |
| FY2018 | Sep 30, 2018 | $3.52M | Feb 8, 2019 |
| FY2018 | Jun 30, 2018 | $3.37M | Feb 8, 2019 |
| FY2018 | Mar 31, 2018 | $11.79M | Feb 8, 2019 |
| FY2018 | Dec 31, 2017 | $3.45M | Feb 8, 2019 |
| FY2018 | Sep 30, 2017 | $3.43M | Feb 8, 2019 |
| FY2018 | Jun 30, 2017 | $3.07M | Feb 8, 2019 |
| FY2018 | Mar 31, 2017 | $3.14M | Feb 8, 2019 |
| FY2018 | Dec 31, 2016 | $30.59M | Feb 8, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.02B | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $981.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $975.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $988.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $51.00M | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | $3.94M | Feb 3, 2020 |
| FY2019 | Sep 30, 2019 | $3.71M | Feb 3, 2020 |
| FY2019 | Jun 30, 2019 | $3.75M | Feb 3, 2020 |
| FY2019 | Mar 31, 2019 | $3.46M | Feb 3, 2020 |
| FY2019 | Dec 31, 2018 | $3.58M | Feb 3, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.45M | Feb 9, 2018 |
| FY2017 | Sep 30, 2017 | $3.43M | Feb 9, 2018 |
| FY2017 | Jun 30, 2017 | $3.07M | Feb 9, 2018 |
| FY2017 | Mar 31, 2017 | $3.14M | Feb 9, 2018 |
| FY2017 | Dec 31, 2016 | $3.17M | Feb 9, 2018 |
| FY2017 | Sep 30, 2016 | $20.62M | Feb 9, 2018 |
| FY2017 | Jun 30, 2016 | $2.97M | Feb 9, 2018 |
| FY2017 | Mar 31, 2016 | $3.83M | Feb 9, 2018 |
| FY2016 | Dec 31, 2015 | $50.00M | Feb 17, 2017 |
| FY2016 | Sep 30, 2015 | $15.23M | Feb 17, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.17B) | Feb 5, 2026 |
| FY2025 | Sep 30, 2025 | ($154.00M) | Feb 5, 2026 |
| FY2025 | Jun 30, 2025 | $383.00M | Feb 5, 2026 |
| FY2025 | Mar 31, 2025 | $268.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $291.00M | Feb 5, 2026 |
| FY2025 | Sep 30, 2024 | $142.00M | Feb 5, 2026 |
| FY2025 | Jun 30, 2024 | $195.00M | Feb 5, 2026 |
| FY2025 | Mar 31, 2024 | $241.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $688.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.26B | Feb 27, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.00M) | Feb 5, 2026 |
| FY2025 | Sep 30, 2025 | ($8.00M) | Feb 5, 2026 |
| FY2025 | Jun 30, 2025 | ($10.00M) | Feb 5, 2026 |
| FY2025 | Mar 31, 2025 | ($13.00M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($21.00M) | Feb 5, 2026 |
| FY2025 | Sep 30, 2024 | ($11.00M) | Feb 5, 2026 |
| FY2025 | Jun 30, 2024 | ($9.00M) | Feb 5, 2026 |
| FY2025 | Mar 31, 2024 | ($9.00M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | ($39.00M) | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | ($39.00M) | Feb 27, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $5.96M | Feb 8, 2019 |
| FY2018 | Dec 31, 2017 | $8.15M | Feb 8, 2019 |
| FY2018 | Dec 31, 2016 | $10.24M | Feb 8, 2019 |
| FY2017 | Dec 31, 2015 | $17.03M | Feb 9, 2018 |
| FY2016 | Dec 31, 2014 | $18.48M | Feb 17, 2017 |
| FY2015 | Dec 31, 2013 | $15.56M | Feb 12, 2016 |
| FY2014 | Dec 31, 2012 | $15.80M | Mar 12, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $432.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $399.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $395.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $442.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $76.00M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $33.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $23.50M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $24.07M | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $34.70M | Feb 8, 2019 |
| FY2017 | Dec 31, 2015 | $42.79M | Feb 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $104.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $16.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | ($56.00M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | ($96.00M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | ($37.00M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($26.26M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($30.03M) | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | ($11.90M) | Feb 8, 2019 |
| FY2017 | Dec 31, 2015 | $35.29M | Feb 9, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $247.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $222.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $181.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $134.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $2.00M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $41.0K | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $70.0K | Feb 3, 2020 |
| FY2018 | Dec 31, 2016 | $267.0K | Feb 8, 2019 |
| FY2017 | Dec 31, 2015 | $731.0K | Feb 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.83B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $16.69B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $15.64B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $15.14B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $16.97B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $21.37B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $12.26B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $12.10B | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $11.93B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $9.59B | Feb 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $6.88B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $6.62B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.64B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $6.83B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $7.86B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.59B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.50B | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $1.44B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $1.12B | Feb 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.70B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $9.79B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $9.00B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.48B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $10.13B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $13.50B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $10.67B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $10.60B | Feb 3, 2020 |
| FY2019 | Dec 31, 2017 | $10.49B | Feb 3, 2020 |
| FY2019 | Dec 31, 2016 | $8.47B | Feb 3, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $755.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $755.00M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $755.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $762.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $746.00M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $7.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $6.50M | Feb 26, 2021 |
| FY2016 | Dec 31, 2016 | $6.50M | Feb 17, 2017 |
| FY2016 | Dec 31, 2015 | $6.50M | Feb 17, 2017 |
| FY2015 | Dec 31, 2014 | $27.17M | Feb 12, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.04B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $6.71B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $5.84B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.16B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $3.90B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.17B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.77B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.65B | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $2.57B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $517.74M | Feb 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $89.00M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $79.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $375.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $191.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $1.42B | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $50.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $83.10M | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | $81.26M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $205.73M | Feb 9, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.75B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.69B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $3.74B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.80B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $3.76B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $4.82B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $572.94M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $522.93M | Feb 3, 2020 |
| FY2018 | Dec 31, 2017 | $497.37M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $198.51M | Feb 9, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 6 | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | 4 | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | 8 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Feb 3, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 6 | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | 4 | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | 7 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 17, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 3, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Feb 3, 2020 |